Femasys Inc. (NASDAQ:FEMY) Sees Significant Growth in Short Interest

Femasys Inc. (NASDAQ:FEMY) was the target of a significant increase in short interest in the month of February. As of February 28th, there was short interest totalling 658,900 shares, an increase of 120.9% from the February 13th total of 298,300 shares. Based on an average daily volume of 270,500 shares, the days-to-cover ratio is presently 2.4 days. Approximately 3.4% of the company’s stock are sold short.

Femasys Stock Performance

Shares of Femasys stock traded up $0.17 during trading on Friday, reaching $1.57. The company’s stock had a trading volume of 543,053 shares, compared to its average volume of 269,067. The company has a 50-day moving average price of $1.32 and a two-hundred day moving average price of $1.20. The firm has a market cap of $35.95 million, a PE ratio of -1.94 and a beta of -2.86. Femasys has a fifty-two week low of $0.86 and a fifty-two week high of $2.12. The company has a current ratio of 3.94, a quick ratio of 3.26 and a debt-to-equity ratio of 0.86.

Hedge Funds Weigh In On Femasys

Institutional investors have recently modified their holdings of the business. Virtu Financial LLC acquired a new position in shares of Femasys in the 4th quarter valued at $25,000. Aljian Capital Management LLC acquired a new position in Femasys in the 3rd quarter valued at $27,000. Jane Street Group LLC acquired a new position in Femasys in the 4th quarter valued at $30,000. XTX Topco Ltd increased its stake in Femasys by 123.9% in the 3rd quarter. XTX Topco Ltd now owns 32,535 shares of the company’s stock valued at $36,000 after buying an additional 18,004 shares during the period. Finally, Citadel Advisors LLC acquired a new position in Femasys in the 4th quarter valued at $45,000. 65.27% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and set a $12.00 price objective on shares of Femasys in a research report on Thursday.

Femasys Company Profile

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.